Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 5/20 | 0.35 |
| ▸ | P2RY6 | Q15077 | 3/20 | 0.35 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | GAPDH | P04406 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.30 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.30 |
| ▸ | MMP1 | P03956 | 1/20 | 0.30 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | MMP9 | P14780 | 1/20 | 0.30 |
| ▸ | MMP12 | P39900 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16214947 | 0.93 | POLB (0.37) | P2RY2P2RY6P2RY14POLBMEN1 | |
| SCHEMBL16214981 | 0.93 | POLB (0.37) | P2RY2P2RY6P2RY14POLBMEN1 | |
| SCHEMBL14102275 | 0.92 | POLB (0.36) | P2RY2P2RY6P2RY14POLBMEN1 | |
| SCHEMBL21418943 | 0.92 | POLB (0.36) | P2RY2P2RY6P2RY14POLBMEN1 | |
| SCHEMBL17972480 | 0.92 | POLB (0.36) | P2RY2P2RY6P2RY14POLBMEN1 | |
| SCHEMBL16576220 | 0.92 | POLB (0.36) | P2RY2P2RY6P2RY14POLBMEN1 | |
| SCHEMBL15109290 | 0.89 | GAPDH (0.33) | GAPDH | |
| SCHEMBL19112430 | 0.86 | P2RY2 (0.40) | P2RY2P2RY6P2RY14P2RY4 | |
| SCHEMBL16255784 | 0.86 | P2RY2 (0.40) | P2RY2P2RY6P2RY14P2RY4 | |
| SCHEMBL16306309 | 0.86 | P2RY2 (0.40) | P2RY2P2RY6P2RY14P2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2615101-B1 | NUCLEOSIDE DERIVATIVES, SYNTHESIS METHODS AND USES THEREOF FOR PREPARING ANTI-TUMOR AND ANTI-VIRUS MEDICAMENTS | HIGH & NEW TECH RESEARCH CENTER HENAN ACADEMY OF SCIENCES (CN) | 2018-10-17 | — | — | EP | disclosed |
| US-9422321-B2 | Pyrimidine nucleoside derivatives, synthesis methods and uses thereof for preparing anti-tumor and anti-virus medicaments | HIGH & NEW TECHNOLOGY RESEARCH CENTER, HENAN ACADEMY OF SCIENCES (CN) | 2016-08-23 | — | — | US | disclosed |
| US-20130303747-A1 | PYRIMIDINE NUCLEOSIDE DERIVATIVES, SYNTHESIS METHODS AND USES THEREOF FOR PREPARING ANTI-TUMOR AND ANTI-VIRUS MEDICAMENTS | HIGH & NEW TECHNOLOGY RESEARCH CENTER, HENAN ACADEMY OF SCIENCES (CN) | 2013-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303747-A1 | PYRIMIDINE NUCLEOSIDE DERIVATIVES, SYNTHESIS METHODS AND USES THEREOF FOR PREPARING ANTI-TUMOR AND ANTI-VIRUS MEDICAMENTS | TYMP, DUT, NUDT1 | P2RY2 261/4885P2RY6 142/4885P2RY14 209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.